Accrol Share Discussion Threads

[mfhmfh] 23/7/2021 16:14

Chairman purchase

[ygor705] 22/7/2021 18:31

Very chunky sales late yesterday and today.

[ygor705] 22/7/2021 18:30

Consensus brokers consensus for normalised eps is 4.43p to 30 April 2022 and 5.16p for following year. That's against 0.17p to 30 Apr 2021. Stockopedia figures.

[bb123] 21/7/2021 10:23

Any comments on the full-year 2021 results presentation?

Do we have any BROKER FORECASTS for Accrol?

[tomps2] 21/7/2021 08:35

Accrol (ACRL) full-year 2021 results presentation

The full management team Dan Wright, Executive Chairman, Gareth Jenkins, CEO, Richard Newman, CFO and Graham Cox, Commercial Director give a comprehensive overview of the turnaround to date.

Watch the video here:

Or listen to the podcast here:

[tomps2] 15/7/2021 08:24

Accrol Group Holdings (ACRL) full-year 2021 results webinar, today (15/07/21) at 1:15pm

As part of the Group’s Financial Results roadshow, Dan Wright, Executive Chairman and Gareth Jenkins, CEO will present full year results followed by Q&A.

Register here:

[zipstuck] 14/7/2021 09:24

Acquisitions & Integrations

Following the acquisition of LTC in November 2020, we have completed the integration of the business and expect to deliver annualised synergy benefits of GBP3.0m - three times greater than originally anticipated at the time of the acquisition. These are being driven through operational improvements across the wider group, including logistics, operational simplification, and procurement. The revenue synergies, which are measured over an agreed period of time, will be lower during this Period, due to the impact of the pandemic, but are expected to benefit the Group in the longer term

In April 2021, the Group acquired the JD business in North Wales, a highly scalable flushable and bio-degradable wet wipe business. Early integration activities have progressed ahead of schedule and initial synergies are expected to be cGBP1m in the first full year of ownership. These will be delivered through operational synergies with the Group's existing facial tissue business, procurement benefits of the enlarged Group, simplification of organisation, and revenue growth opportunities, as the product offering to Accrol's existing customer base now includes its range of wet wipes. The Group's expectation with additional capital investment is to build a wet wipe business of significant scale by 2024.

[ygor705] 14/7/2021 08:29

The numbers are ahead of consensus forecasts so I would not expect the share price to come to much harm from here. The manufacturing side of the business looks to be moving towards complete automation by 2023 and distortions to the demand for tissue paper are steadily working there way out of the system. Firm hold for me.

[value viper] 14/7/2021 08:13

Directors to buy now results outI would think so (need to)

[bookbroker] 14/7/2021 07:57

What a load of waffle, ‘anticipated recovery’!

[masurenguy] 14/7/2021 07:54

Positive results statement !

"Despite the challenges of the pandemic, the Group was able to deliver on its strategic objectives. The business was successfully scaled, through the acquisition of Leicester Tissue Company and diversified via the John Dale wet wipes acquisition.

The team's continued focus on operational efficiency delivered an overall improvement in reported gross margin of 580ppt to 27.7% and a tripling of initial expectations on LTC synergies. Adjusted EBITDA rose by 47% in the year to £15.6m. Despite the volatility created in the tissue market by the pandemic limiting the Group's revenue growth to 1.4% in the Period, Accrol outperformed its peers and increased its market share to 15.9% from 13.1% in FY21. Over the last 2 years the like for like sales (excluding Away from Home) have grown by 16% from £117.6m to £136.6m and market share growth for the Group has risen from 12% to 15.9%. With the business in excellent operational shape, scalable foundations for growth in place, and a strong market position, the Group is very well placed to benefit from the anticipated recovery in tissue volumes, as the effects of the pandemic unwind.

The Group expects to see FY22 exit run rates to be significantly improved with the major discounters expecting uplift in tissue volumes and Accrol's recently secured additional new business has increased confidence for FY23 revenues and returns. Trading in line with forecasts in FY22 to date and the Board remains confident in the long-term prospects for Accrol"

[leadersoffice] 14/7/2021 07:09

Dividend restored 0.5p

[value viper] 13/7/2021 14:23

My gut feel - a buy now alsoWe will have to wait and see

[investorsiba] 13/7/2021 10:43

Still they sell, day before a trading update

My short has this back at 30p before too long imo

[investorsiba] 13/7/2021 08:20

No way oversold Way too many sellers still further to drop imho

[ptolemy] 12/7/2021 14:29

Results webinar on Thursday:

[ptolemy] 12/7/2021 12:19

oversold - I agree.

[masurenguy] 09/7/2021 15:58

This is looking oversold and I like the synergy of the John Dale acquisition announced in April. With Premier Miton recently increasing their stake to 10%, plus results due next week, I'm back in today having exited @60p at the end of March.

[ptolemy] 09/6/2021 12:29

Technically the chart looks good for a move up.

[stevieweebie2] 02/6/2021 16:39

Ive been in the UK tissue Industry just over 40yrs now and I know the Tejanis and the guys at Natsons and the guys at Task and lots of mill Managers and owners and I dont often post on here for obvious reasons but when I read the diatribe above from Mr 1973 I tend to take the bait,I can tell you, he knows nothing about the tissue Industry and for balance knowing what I know I still hold and whilst disapointed the downside from here is minimal, as airbus says, its oversold.DYOR

[arbus5000] 02/6/2021 11:39

Its over sold now tbh, instead of selling my small holding, I'm buying more.

[stevesham] 02/6/2021 07:01

I certainly wouldn't buy it now, out and staying out